Dishman Carbogen Amcis Approves ₹50 Cr NCD Issue

Dishman Carbogen Amcis Ltd has announced the approval for issuance of non-convertible debentures (NCDs) worth up to ₹50 crores, marking a significant capital raising initiative by the pharmaceutical company. The debentures are structured with attractive terms designed to appeal to income-seeking investors.

Debenture Structure and Terms

The approved NCDs will carry a coupon rate of 10.00% per annum, with interest payments scheduled on a quarterly basis. This payment frequency ensures regular income flow for investors throughout the tenure of the debentures.

Parameter	Details
Issue Size	Up to ₹50.00 crores
Coupon Rate	10.00% per annum
Payment Frequency	Quarterly
Security Type	Non-Convertible Debentures

Security Features

The debentures will be secured through multiple layers of protection to safeguard investor interests. The company has structured the NCDs with property-backed security, providing tangible asset coverage for the debt instruments. Additionally, corporate guarantees will further strengthen the security framework, offering investors enhanced protection against default risk.

Strategic Implications

This debt fundraising initiative reflects Dishman Carbogen Amcis Ltd's strategy to optimize its capital structure through debt financing. The 10.00% coupon rate positions the debentures competitively in the current market environment, while the quarterly payment structure caters to investors seeking regular income streams. The secured nature of these debentures, backed by properties and corporate guarantees, demonstrates the company's commitment to providing robust investor protection.

The approval of this NCD issuance provides Dishman Carbogen Amcis with access to up to ₹50.00 crores in funding, which can support various business operations and growth initiatives while maintaining the company's equity structure.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.01%	+8.65%	+18.70%	+0.79%	-3.34%	+89.17%

Dishman Carbogen Amcis Limited has announced that its board of directors will convene on December 27 to discuss funding arrangements through Non-Convertible Debentures (NCDs). This scheduled meeting represents an important corporate governance milestone for the pharmaceutical company as it explores debt financing options.

Board Meeting Details

The upcoming board meeting will focus specifically on evaluating funding strategies through NCDs, which are debt instruments that cannot be converted into equity shares. This financing mechanism allows companies to raise capital while maintaining their existing equity structure.

Meeting Parameter	Details
Date	December 27
Purpose	Discuss NCD funding arrangements
Company	Dishman Carbogen Amcis Limited
Instrument Type	Non-Convertible Debentures

Significance of NCD Funding

Non-Convertible Debentures serve as an alternative financing tool for companies seeking to raise capital without diluting existing shareholding. For pharmaceutical companies like Dishman Carbogen Amcis, such funding mechanisms can provide the necessary resources for business operations, research and development activities, or expansion plans.

Corporate Governance Process

The scheduled board meeting demonstrates the company's adherence to proper corporate governance procedures. By convening the board to discuss funding options, Dishman Carbogen Amcis ensures that all financing decisions undergo appropriate evaluation and approval processes before implementation.

This development will be closely watched by investors and stakeholders as the company moves forward with its capital structure planning and funding strategy decisions.